top of page

Third Harmonic Bio is nearing an IND submission to put a new oral KIT inhibitor into the clinic

  • blonca9
  • Mar 4, 2024
  • 1 min read

CEO Natalie Holles describes how learnings from a setback from the company's first asset have resulted in a new program that she believes can have wide utility in multiple mast cell mediated inflammatory conditions.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page